This framework incorporates clinical parameters, laboratory values, and PSMA PET imaging findings to define disease progression, drawing from the structure of the previously established Prostate Cancer Working Group 2 (PCWG2) criteria. The gene discussed is FOLH1; the disease is prostate carcinoma.